The Executive Office of Health & Human Services

Pharmacy and Therapeutics Committee Meeting Minutes

Tuesday, April 12th, 2022
8:00 AM
Location: RI EOHHS Virks Building
3 West Road, Cranston, RI 02920

P & T Members Present: Greg Allen, MD
Todd Brothers, PharmD
Bill Quirk, RPh
Matt Salisbury, MD
Tracey Taviera, PharmD
Rick Wagner, MD

Absent: Jerry Fingerut, MD, Medical Director, (EOHHS)
Nickolai Morin, PharmD

Others Present: Ann Bennett, MHSA (Gainwell Technologies)
Dezeree Hodish, Assistant Director Financial and Contract Management (EOHHS)
Karen Mariano, RPh (Gainwell Technologies)
Kathryn Novak, RPh (Magellan Medicaid Administration)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:18 am. Chairman Tracey Taviera called the meeting to order and asked for introductions from the committee and those supporting the meeting. The December 12th, 2021 meeting minutes were reviewed and by vote were accepted as presented.

Public testimony included the following speakers and topics.
Follow up information should be sent to karen.mariano@gainwelltechnologies.com for distribution to the committee.

Speakers	Affiliation	Topic
Amy Tomasella	Abbvie	Rinvoq (upadactinib)
William Wu	Viofor	Veltassa (patiromer)
Peter Drevins	Zeland	Zegalogue (dasiglucagon)

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee.

Therapeutic Categories		Vote:Yes	Vote:No	Abstain	Motion & Note
Blood Modifying Agents	Antihyperuricemics	all			No new information in this class. No recommended changes to the current preferred agents.
	Bile Salts	all			Ocalivia FDA communications regarding PBC with advanced cirrhosis of live to risk of hepatic function. New products Bylvay (treating pruritus) and Livmarli (treating cholestatic pruritis). No recommended changes to the current preferred agents.
	Colony Stimulating Factors	all			New category for committee. Discussion: How is non-utilization reported? It is reported within the group as compliant or non-compliant to the preferred (P) agent of the PDL. Recommendation: add Granix syringe, Neupogen disposable syringe and vial, and Nyvepria as preferred.
	Erythropoiesis Stimulating Proteins	all			Retacrit manufacturer anticipates a supply issue. Recommendation: add Epogen as preferred.

Therapeutic Categories	(continued)		Vote:Yes	Vote:No	Abstain	Motion & Note
	Phosphate Binders		all			No new information in this class. Monitoring brand and generic pricing. Recommendation: Move calcium acetate tablets to non-preferred (NP) and add Renagel as preferred.
	Potassium Binders		all			No new information in this class. Discussion: one NP product has different mechanism of action. No recommended changes to the current preferred agents.
Endocrine Agents	Androgenic Agents		all			No new information in this class. Highest utilization is a non-preferred agent. Discussion: Is the PDL trying to get utilization of the NP agent? Should this go to DUR to contact prescriber? No, the utilization is most likely because of third party payor requiring the NP product. Most cost effect products are Androgel and Androderm. Recommendation: move Androgel gel packets to NP.
	Bone Resorption Inhibitors		all			North American Menopause Society (NAMS) updated recommendations for osteoporosis and management in postmenopausal women. No recommended changes to the current preferred agents.
	Enzyme Replacement, Gaucher's		all			New category for committee. Recommendation: add Zavesca (brand) as preferred.
	Glucagon Agents		all			GVOKE now available a single dose formulation vial and syringe. Zegalogue available a single dose autoinjector. Recommendations: add Glucagon ER Kit (Fresenius) and Zegalogue autoinjector as preferred. Change Glucagon ER Kit (Lilly) to NP.
	Growth Hormones		all			New product Skytrofa. No recommended changes to the current preferred agents.
	Hypoglycemics	Alpha Glucosidase Inhibitors	all			AHA published state on magnement of cardiovascular risk factors for adults with T2DM. Discussion: Coverage of drugs for weight-loss as it is a healthcare issue that impacts cardiovascular health. No changes to current recommendations.
		Incretin Mimetics / Enhancers	all			Bydueron Pen and Bcise now approved for adjunct to diet and exercise. Recommendation: Move Glyxambi to NP and change Ozempic to preferred.
		Insulins	all			New generics/biologics: Semglee (insulin glargine-yfgn) now approved as an interchangeable biosimilary to insulin glargine (Lantus). Discussion: Has any state put this on the PDL? No. Recommendations: Change Novolog Mix vial to NP.
		Meglitinides	all			No new information. No recommended changes to the current preferred agents.
		Metformins	all			No new information. No recommended changes to the current preferred agents.
		SGLT2s	all			Updated information: Farxiga and Jardiance. No recommended changes to the current preferred agents.
		Sulfonylureas	4	2		No new information. Discussion: Motion to remove glimepiride to remove it from the PDL. Motion made MS; 2nd by TB. RW would prefer to move this to DUR to see if there is a hypoglycemic event in patients; TT, does the system capture the hypoglycemic event? No. RW, would not like to take the product off without looking at the events, concern about compliance? MS we are supplying patients with wide range of products for treatment of hyperglycemia. TB what is current utilization? Vote on motion to move glimepiride to NP and accept remaining recommendations. Results: Motion passes with 4 in support and 2 against motion. Patients who are currently (within 90 days of date of service on submitted claim) being treated with glimepiride will continue with therapy without prior authorization.

Therapeutic Categories	(continued)	Vote:Yes	Vote:No	Abstain	Motion & Note
	Thiazolidinediones	all			No recommended changes to the current preferred agents.
	Pancreatic Enzyme	all			Recommendations: Change Pancreaze to preferred and Zenpep to NP.
	Pituitary Suppressive Agents, LHRH	all			New category for review. Recommendation: add Fensolvi as preferred.
	Progestins for Cachexia	5		1	No new information. Discussion: Can Megace ES be added? Not cost effective. Can this go to DUR? There is no utilization, so this is not a DUR topic to review. Perhaps look at longer period of time, revisit next meeting. No recommended changes to the current preferred agents.
GI Agents	Antiemetics	all			No new information. Discussion: has any other state looked at this category? Any consideration to add drug for nausea in pregnancy? FFS does not typically have a lot of pregnant women. No recommended changes to the current preferred agents.
	GI Motility, Chronic	all			No new information. No recommended changes to the current preferred agents.
	H. Pylori Agents	all			No new information. No recommended changes to the current preferred agents.
	Proton Pump Inhibitors	all			No new information. Discussion: utilization of Nexium suspension. No recommended changes to the current preferred agents.
	Ulcerative Colitis Agents	all			No new information. This is more traditional class of UC items. Noncompliance is class is with mesalamine products. All CAM agents go with CAMS. No recommended changes to the current preferred agents.
Other, New category	Botulinum Toxins	all			New category. Many indications. Recommendation: add Dysport as preferred agent.
	Immunomodulators, Asthma	all			New category. Recommendation: add Fasenra pen and syringe, and Xolair syringe.

2022 Schedule

June 7th
September 20th
December 13th

Adjournment

The meeting adjourned at 9:43 AM